[go: up one dir, main page]

PT1441708E - Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo - Google Patents

Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo Download PDF

Info

Publication number
PT1441708E
PT1441708E PT02789421T PT02789421T PT1441708E PT 1441708 E PT1441708 E PT 1441708E PT 02789421 T PT02789421 T PT 02789421T PT 02789421 T PT02789421 T PT 02789421T PT 1441708 E PT1441708 E PT 1441708E
Authority
PT
Portugal
Prior art keywords
methods
therapies
compositions
aldehyde dehydrogenase
dehydrogenase inhibitors
Prior art date
Application number
PT02789421T
Other languages
English (en)
Inventor
Seth Lederman
Original Assignee
Krele Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krele Pharmaceuticals Llc filed Critical Krele Pharmaceuticals Llc
Publication of PT1441708E publication Critical patent/PT1441708E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Addiction (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
PT02789421T 2001-11-05 2002-11-04 Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo PT1441708E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33890101P 2001-11-05 2001-11-05

Publications (1)

Publication Number Publication Date
PT1441708E true PT1441708E (pt) 2009-06-18

Family

ID=23326616

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02789421T PT1441708E (pt) 2001-11-05 2002-11-04 Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo

Country Status (10)

Country Link
US (3) US20030087814A1 (pt)
EP (1) EP1441708B1 (pt)
AT (1) ATE427745T1 (pt)
AU (1) AU2002354017B2 (pt)
CA (1) CA2463987C (pt)
DE (1) DE60231896D1 (pt)
DK (1) DK1441708T3 (pt)
NZ (1) NZ532583A (pt)
PT (1) PT1441708E (pt)
WO (1) WO2003039525A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1441708E (pt) 2001-11-05 2009-06-18 Krele Pharmaceuticals Llc Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
PT2101569E (pt) * 2006-12-14 2012-01-13 Teva Pharma Base de rasagilina sólida cristalina
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
NO2501234T3 (pt) * 2009-11-20 2018-02-10
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
PT2611440T (pt) * 2010-09-01 2017-04-26 Tonix Pharmaceuticals Inc Tratamento para a dependência de cocaína
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
CN110152005B (zh) 2013-03-15 2023-08-04 通尼克斯制药控股有限公司 环苯扎林盐酸盐和阿米替林盐酸盐的低共熔混合物配制剂
CN112618494B (zh) 2014-09-18 2023-06-30 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
IL275289B2 (en) 2017-12-11 2024-01-01 Tonix Pharma Holdings Ltd Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567814A (en) 1948-03-26 1951-09-11 Ayerst Mckenna & Harrison Tetraethyl thiuram disulfide alcoholism treatment composition
US3155584A (en) * 1962-12-03 1964-11-03 Abbott Lab Compositions and method of inhibiting monoamine oxidase and treating hypertension
SE404186B (sv) * 1975-06-09 1978-09-25 Astra Laekemedel Ab Forfarande for framstellning av cyklopropanolderivat
US4678809A (en) 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4565689A (en) * 1985-04-12 1986-01-21 Wirth Maschinen-Und Bohrgerate-Fabrik Gmbh Method for treating the effects of alcohol
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
WO1992005787A1 (en) * 1990-10-01 1992-04-16 Radecki Thomas E Drug therapy for alcohol abusers
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
WO1992021333A2 (en) * 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
EP0520325A1 (de) 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP0593807A1 (en) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
DE4428444A1 (de) 1994-08-11 1996-02-15 Dresden Arzneimittel Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
BR9501972A (pt) * 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
EP0906090A1 (en) 1996-03-15 1999-04-07 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
WO1998000332A1 (fr) * 1996-06-28 1998-01-08 Etienne Dallet Engin, tel que notamment cycle, a propulsion humaine
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
SK5812000A3 (en) 1997-10-28 2000-12-11 Schering Corp Method of reducing craving in mammals
EP1077697B1 (en) * 1998-05-12 2006-07-19 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
PT1441708E (pt) 2001-11-05 2009-06-18 Krele Pharmaceuticals Llc Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo

Also Published As

Publication number Publication date
US20120101154A1 (en) 2012-04-26
US20030087814A1 (en) 2003-05-08
WO2003039525A1 (en) 2003-05-15
CA2463987C (en) 2011-03-08
US20090005441A1 (en) 2009-01-01
AU2002354017B2 (en) 2007-08-16
CA2463987A1 (en) 2003-05-15
US8093300B2 (en) 2012-01-10
EP1441708B1 (en) 2009-04-08
EP1441708A1 (en) 2004-08-04
DE60231896D1 (de) 2009-05-20
ATE427745T1 (de) 2009-04-15
EP1441708A4 (en) 2007-05-23
DK1441708T3 (da) 2009-07-06
US8481599B2 (en) 2013-07-09
NZ532583A (en) 2006-12-22

Similar Documents

Publication Publication Date Title
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
WO2005000213A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with enzyme inhibitors
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
WO2004037205A3 (en) LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL
PL375900A1 (en) Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer
WO2004093826A3 (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
IL157821A0 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
WO2004089353A8 (en) Methods for treatment of parkinson's disease
GEP20084317B (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
PT1441708E (pt) Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
TW200505829A (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
WO2005018535A3 (en) Compositions and methods for treatment of severe acute respiratory syndrome (sars)
HK1074592A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2005000212A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
WO2001034172A3 (en) Methods and compositions for treating reward deficiency syndrome
EP1550443A4 (en) COMPOSITION AGAINST STRESS-BASED DISEASES
WO2001088530A3 (de) Verfahren zum selektieren von inhibitoren für enzyme
WO2004098505A3 (en) Attenuation of ischemia/reperfusion injury
ZA200502909B (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2.
AU2003274565A8 (en) Composition for the treatment of nasopharyngeal carcinoma and method of use thereof
MY142040A (en) Nitrosophenols and c-nitrosoanilines as polymerization inhibitors
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
WO2005021095A3 (en) Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors